Precision BioSciences Inc (DTIL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $288.76M
Last updated: Nov 17, 2026 at 11:04 AM ET
Precision BioSciences Inc (DTIL) Financials: Revenue, Profit and Cash Flow
Precision BioSciences reported revenue of $34.26M for the fiscal year ended Dec 31, 2025, down 50.1% from the year before. That year, net income was -$45.72M with a net margin of -133.4%, operating cash flow was -$65.84M and free cash flow was -$65.93M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$7.59M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $7.01M, a compound annual rate of 19.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $34.26M | -50.1% | 100.0% | -152.2% | -133.4% |
| Dec 2024 | $68.70M | +41.0% | 100.0% | -38.1% | 10.4% |
| Dec 2023 | $48.73M | +94.1% | 100.0% | -89.8% | -125.8% |
| Dec 2022 | $25.10M | -78.3% | 100.0% | -248.3% | -444.8% |
| Dec 2021 | $115.53M | +375.7% | 100.0% | -34.1% | -26.5% |
| Dec 2020 | $24.29M | +9.2% | 100.0% | -452.2% | -445.5% |
| Dec 2019 | $22.24M | +104.3% | 100.0% | -392.1% | -443.2% |
| Dec 2018 | $10.88M | +67.8% | 100.0% | -440.2% | -423.0% |
| Dec 2017 | $6.48M | -7.6% | 100.0% | -338.9% | -325.4% |
| Dec 2016 | $7.01M | N/A | 100.0% | -125.8% | -117.6% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34.26M | $68.70M | $48.73M | $25.10M | $115.53M | $24.29M | $22.24M | $10.88M | $6.48M | $7.01M |
| Gross profit | $34.26M | $68.70M | $48.73M | $25.10M | $115.53M | $24.29M | $22.24M | $10.88M | $6.48M | $7.01M |
| Research and development | $54.17M | $59.56M | $53.38M | $46.12M | $115.24M | $98.06M | $82.42M | $45.12M | $20.32M | $9.10M |
| Operating income | -$52.15M | -$26.16M | -$43.74M | -$62.31M | -$39.38M | -$109.83M | -$87.20M | -$47.91M | -$21.97M | -$8.83M |
| Net income | -$45.72M | $7.17M | -$61.32M | -$111.64M | -$30.60M | -$108.18M | -$98.55M | -$46.04M | -$21.10M | -$8.25M |
| EBITDA | -$41.43M | $7.40M | -$34.94M | -$53.87M | -$26.58M | -$100.02M | N/A | -$43.68M | -$20.42M | -$8.19M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $10.84M | $34.20M | $13.00K | $18.00K | $29.00K | $638.00K | $576.00K | $49.90M | $17.58M | $7.04M |
| Gross profit | $0 | $0 | $10.84M | $34.20M | $13.00K | $18.00K | $29.00K | $638.00K | $576.00K | $49.90M | $17.58M | $7.04M |
| Operating income | -$20.43M | -$19.16M | -$9.07M | $12.51M | -$20.67M | -$21.88M | -$22.11M | -$24.85M | -$21.27M | $24.15M | -$4.19M | -$14.89M |
| Net income | -$7.59M | -$32.65M | -$18.44M | $20.13M | -$21.77M | -$23.52M | -$20.57M | -$17.75M | -$16.43M | $32.75M | $8.59M | -$16.29M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $23.91M by $86.91M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $154.42M | $136.39M | $159.78M | $238.17M | $211.50M | $150.16M | $235.23M | $138.60M | $72.68M | $98.41M |
| Current assets | $118.74M | $94.99M | $136.36M | $199.10M | $161.75M | $105.56M | $193.67M | $115.67M | $64.33M | $94.40M |
| Cash and equivalents | $110.82M | $85.90M | $116.68M | $189.58M | $143.66M | $89.80M | $180.89M | $103.19M | $62.80M | $93.42M |
| Total liabilities | $62.17M | $80.00M | $140.92M | $177.74M | $120.33M | $105.73M | $96.92M | $98.64M | $99.05M | $103.16M |
| Short-term debt | $1.51M | $1.32M | $22.41M | $0 | $1.82M | $1.93M | $6.83M | $3.25M | $1.51M | N/A |
| Long-term debt | $22.40M | $22.32M | $0 | $22.22M | $2.48M | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $92.25M | $56.39M | $18.86M | $60.43M | $91.17M | $44.42M | $138.31M | $39.95M | -$26.37M | -$4.75M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $120.38M | $125.92M | $143.89M | $154.42M | $93.51M | $108.93M | $124.41M | $136.39M | $153.26M | $165.80M | $184.74M | $159.78M |
| Total liabilities | $68.60M | $80.63M | $67.79M | $62.17M | $76.88M | $74.87M | $75.07M | $80.00M | $88.39M | $91.09M | $147.53M | $140.92M |
| Cash and equivalents | $81.70M | $86.08M | $99.37M | $110.82M | $44.87M | $62.24M | $77.22M | $85.90M | $98.75M | $123.57M | $137.77M | $116.68M |
| Shareholder equity | $51.77M | $45.29M | $76.10M | $92.25M | $16.63M | $34.05M | $49.34M | $56.39M | $64.87M | $74.71M | $37.21M | $18.86M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$65.84M | -$58.45M | -$84.11M | -$45.75M | -$10.85M | -$87.39M | -$71.02M | -$51.72M | -$24.17M | $92.27M |
| Capital expenditures | $85.00K | $250.00K | $1.96M | $3.32M | $5.05M | $5.03M | $24.67M | $15.68M | $5.57M | $2.08M |
| Free cash flow | -$65.93M | -$58.70M | -$86.07M | -$49.07M | -$15.91M | -$92.42M | -$95.68M | -$67.40M | -$29.73M | $90.20M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $12.43M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | $2.62M | N/A | N/A | N/A |
| Investing cash flow | -$634.00K | -$215.00K | $5.83M | -$3.32M | -$5.80M | -$5.03M | -$24.67M | -$15.66M | -$5.51M | -$2.08M |
| Financing cash flow | $95.16M | $50.45M | $5.39M | $94.98M | $70.52M | $1.33M | $173.37M | $107.78M | -$937.00K | -$12.38M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.13M | -$13.44M | -$11.94M | -$11.25M | -$15.27M | -$20.27M | -$19.05M | -$18.68M | -$5.91M | -$14.87M | -$18.98M | -$8.42M |
| Capital expenditures | N/A | N/A | $18.00K | $19.00K | $15.00K | $2.00K | $64.00K | $97.00K | $39.00K | $28.00K | $86.00K | $26.00K |
| Free cash flow | N/A | N/A | -$11.96M | -$11.27M | -$15.29M | -$20.27M | -$19.12M | -$18.78M | -$5.95M | -$14.90M | -$19.07M | -$8.45M |
Frequently Asked Questions About DTIL
What is Precision BioSciences' annual revenue?
Precision BioSciences reported revenue of $34.26M for the fiscal year ended Dec 31, 2025.
How fast is Precision BioSciences' revenue growing?
Revenue was down 50.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.9%.
Is Precision BioSciences profitable?
No. Precision BioSciences reported net income of -$45.72M for the fiscal year ended Dec 31, 2025, with a net margin of -133.4%.
How much free cash flow does DTIL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$65.84M minus capital expenditures of $85.00K produced free cash flow of -$65.93M.
How much debt does Precision BioSciences have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $22.40M, short-term debt of $1.51M and cash and equivalents of $110.82M.
DTIL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors